{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:30:21Z","timestamp":1761514221832},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T00:00:00Z","timestamp":1530835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A sensitive, selective rapid bioanalytical assay method was developed and quantification of iloperidone (ILP) and olanzapine (OLZ) in rat plasma was done by mass spectrometry. Systematic sample preparation and extraction procedure were carried out by supported liquid extraction using dichloromethane to extract both the eluents (ILP and OLZ) from rat plasma samples. The extorted samples were injected on a selective Waters XTerra\u00ae C18 reverse-phase bonded column (250 \u00d7 4.6 mm i.d., 5 \u03bcm) using acetonitrile and 15 mM ammonium formate containing 0.05% trifluoroacetic acid (60:40 v\/v) for isocratic elution mode and detected by mass spectrometry. Calibration curves were drawn with the respective assay statistical data and showed linear regression coefficients greater than 0.9996 over the concentration ranges 2\u20135,000 ng\/mL for ILP and OLZ, respectively. The absolute mean recoveries were found to be in the replicate range of 87.12\u201394.47%, respectively. The obtained results by the method revealed good intra and interday assay performance in terms of 1.70\u20135.90% precision and 0\u20135% accuracy. The validated bioassay method has been successfully applied to the pharmacokinetics in rats.<\/jats:p>","DOI":"10.1093\/chromsci\/bmy063","type":"journal-article","created":{"date-parts":[[2018,6,16]],"date-time":"2018-06-16T19:08:14Z","timestamp":1529176094000},"page":"879-887","source":"Crossref","is-referenced-by-count":8,"title":["Supported liquid extraction and LC\u2013MS-MS determination of iloperidone and olanzapine in rat plasma: Application to a pharmacokinetic study"],"prefix":"10.1093","volume":"56","author":[{"given":"Ch","family":"Gangu Naidu","sequence":"first","affiliation":[{"name":"Department of S&H, Vignan\u2019s Foundation For Science, Technology and Research University (VFSTRU), Vadlamudi, Guntur, Andhra Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Nageswara Rao","sequence":"additional","affiliation":[{"name":"Analytical Chemistry Division, Discovery Laboratory D215, Indian Institute of Chemical Technology, Tarnaka, Hyderabad, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A V","family":"Prasada Rao","sequence":"additional","affiliation":[{"name":"Department of Inorganic and Analytical chemistry, Andhra University, Visakhapatnam, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Nagesh Kumar","sequence":"additional","affiliation":[{"name":"Daicel Chiral Technologies India Pvt. Ltd, Shamirpet, Hyderabad, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raju","family":"Padiya","sequence":"additional","affiliation":[{"name":"Pharmacology Division, Indian Institute of Chemical Technology, Tarnaka, Hyderabad, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Madhusudhan Rao","sequence":"additional","affiliation":[{"name":"Department of S&H, Vignan\u2019s Foundation For Science, Technology and Research University (VFSTRU), Vadlamudi, Guntur, Andhra Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,7,6]]},"reference":[{"key":"2019071815300507500_bmy063C1","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0924-977X(99)80327-7","article-title":"Iloperidone: a novel dopamine\/serotonin antagonist with a unique preclinical profile","volume":"9","author":"Kalkman","year":"1999","journal-title":"European Neuropsychopharmacology"},{"key":"2019071815300507500_bmy063C2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0924-977X(02)80382-0","article-title":"Iloperidone is effective and well tolerated in the long term treatment of schizophrenia and schizoaffective disorder","volume":"12","author":"Fairweather","year":"2002","journal-title":"European Neuropsychopharmacology"},{"key":"2019071815300507500_bmy063C3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.schres.2011.05.018","article-title":"Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis","volume":"131","author":"Citrome","year":"2011","journal-title":"Schizophrenia Research"},{"key":"2019071815300507500_bmy063C4","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clinthera.2011.03.006","article-title":"Iloperidone for the management of adults with schizophrenia","volume":"33","author":"Crabtree","year":"2011","journal-title":"Clinical Therarapeutics"},{"key":"2019071815300507500_bmy063C5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/CE.S114094","article-title":"Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy","volume":"11","author":"Tonin","year":"2016","journal-title":"Core Evidence"},{"key":"2019071815300507500_bmy063C6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0278-5846(01)00307-4","article-title":"Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone","volume":"26","author":"Subramanian","year":"2002","journal-title":"Progress in Neuropsychopharmacology and Biological Psychiatry"},{"key":"2019071815300507500_bmy063C7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3371\/CSRP.6.1.5","article-title":"Iloperidone for the treatment of schizophrenia: an updated clinical review","volume":"6","author":"Weiden","year":"2012","journal-title":"Clinical Schizophrenia and Related Psychoses"},{"key":"2019071815300507500_bmy063C8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0006-8993(02)03570-9","article-title":"Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism","volume":"956","author":"Ichikawa","year":"2002","journal-title":"Brain Research"},{"key":"2019071815300507500_bmy063C9","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S0893-133X(01)00285-8","article-title":"Extended radioligand binding profile of iloperidone: a broad spectrum dopamine\/serotonin\/norepinephrine receptor antagonist for the management of psychotic disorders","volume":"25","author":"Kalkman","year":"2001","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"key":"2019071815300507500_bmy063C10","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0024-3205(03)00419-3","article-title":"Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha 2C, 5-HT6, and 5-HT1A receptors","volume":"73","author":"Kalkman","year":"2003","journal-title":"Life Sciences"},{"key":"2019071815300507500_bmy063C11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0014-2999(96)00840-0","article-title":"Iloperidone binding to human and rat dopamine and 5-HT receptors","volume":"317","author":"Kongsamut","year":"1996","journal-title":"European Journal of Pharmacology"},{"key":"2019071815300507500_bmy063C12","author":"Strupczewski","year":"1990"},{"key":"2019071815300507500_bmy063C13","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s40263-013-0105-7","article-title":"A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach","volume":"27","author":"Citrome","year":"2013","journal-title":"CNS Drugs"},{"key":"2019071815300507500_bmy063C14","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1742-1241.2009.02142.x","article-title":"Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic","volume":"63","author":"Citrome","year":"2009","journal-title":"International Journal of Clinical Practice"},{"key":"2019071815300507500_bmy063C15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0091-3057(93)90079-9","article-title":"Effects of atypical antipsychotic agents on social behavior in rodents","volume":"45","author":"Corbett","year":"1993","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"2019071815300507500_bmy063C16","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/archpsyc.64.4.442","article-title":"Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials","volume":"64","author":"Scherk","year":"2007","journal-title":"Archives of General Psychiatry"},{"key":"2019071815300507500_bmy063C17","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejphar.2007.11.078","article-title":"Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution","volume":"585","author":"VanderZwaal","year":"2008","journal-title":"European Journal of Pharmacology"},{"key":"2019071815300507500_bmy063C18","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(03)13306-5","article-title":"New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis","volume":"361","author":"Leucht","year":"2003","journal-title":"Lancet"},{"key":"2019071815300507500_bmy063C19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology"},{"key":"2019071815300507500_bmy063C20","volume-title":"Martindale: the complete drug reference","author":"Sweetman","year":"2002","edition":"33rd ed"},{"key":"2019071815300507500_bmy063C21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jchromb.2013.03.026","article-title":"Simultaneous determination of iloperidone and its two active metabolites in human plasma by liquid chromatography\u2013tandem mass spectrometry: application to a pharmacokinetic study","volume":"928","author":"Jia","year":"2013","journal-title":"Journal of Chromatography B"},{"key":"2019071815300507500_bmy063C22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0378-4347(95)00114-X","article-title":"Picogram determination of iloperdine in human plasma by solid-phase extraction and by high-performance liquid chromatography-selected-ion monitoring electrospray mass spectroscopy","volume":"669","author":"Mutlib","year":"1995","journal-title":"Journal of Chromatography B: Biomedical Sciences and Applications"},{"key":"2019071815300507500_bmy063C23","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.4155\/bio.10.65","article-title":"Elimination of LC\u2013MS\/MS matrix effect due to phospholipids using specific solid-phase extraction elution conditions","volume":"2","author":"Lahaie","year":"2010","journal-title":"Bioanalysis"},{"key":"2019071815300507500_bmy063C24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jchromb.2006.12.030","article-title":"Systematic and comprehensive strategy for reducing matrix effects in LC\/MS\/MS analyses","volume":"852","author":"Chambers","year":"2007","journal-title":"Journal of Chromatography B"},{"key":"2019071815300507500_bmy063C25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2174\/138920006777697927","article-title":"LC\u2013MS development strategies for quantitative bioanalysis","volume":"7","author":"Jemal","year":"2006","journal-title":"Current Drug Metabolism"},{"key":"2019071815300507500_bmy063C26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jchromb.2005.01.012","article-title":"Simultaneous determination of norethindrone and ethinyl estradiol in human plasma by high performance liquid chromatography with tandem mass spectrometry experiences on developing a highly selective method using derivatization reagent for enhancing sensitivity","volume":"825","author":"Li","year":"2005","journal-title":"Journal of Chromatography B"},{"key":"2019071815300507500_bmy063C27","author":"Wenkui Li, S.W., Mujamdar, T., Smith,T., Bryant, M., L. S. Tse, F"},{"key":"2019071815300507500_bmy063C28","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/(SICI)1097-0231(19990630)13:12<1175::AID-RCM639>3.0.CO;2-0","article-title":"The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds","volume":"13","author":"Bonfiglio","year":"1999","journal-title":"Rapid Communications in Mass Spectrometry"},{"key":"2019071815300507500_bmy063C29","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.clinbiochem.2004.11.007","article-title":"Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry","volume":"38","author":"Taylor","year":"2005","journal-title":"Clinical Biochemistry"},{"key":"2019071815300507500_bmy063C30","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1021\/cc010039f","article-title":"Scope and limitations of solid-supported liquid-liquid extraction for the high-throughput purification of compound libraries","volume":"3","author":"Breitenbucher","year":"2001","journal-title":"Journal of Combinatorial Chemistry"},{"key":"2019071815300507500_bmy063C31","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/bmc.1597","article-title":"Simultaneous determination of fluoxetine and its major active metabolite norfluoxetine in human plasma by LC-MS\/MS using supported liquid extraction","volume":"25","author":"Li","year":"2011","journal-title":"Biomedical Chromatography"},{"key":"2019071815300507500_bmy063C32","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jpba.2008.08.001","article-title":"An improved LC\u2013ESI\u2013MS\u2013MS method for simultaneous quantitation of rosiglitazone and N-desmethyl rosiglitazone in human plasma","volume":"48","author":"O\u2019Maille","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"2019071815300507500_bmy063C33","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1016\/j.jchromb.2009.07.029","article-title":"Rapid determination of cyanide in human plasma and urine by gas chromatography-mass spectrometry with two-step derivatization","volume":"877","author":"Liu","year":"2009","journal-title":"Journal of Chromatography B"},{"key":"2019071815300507500_bmy063C34","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/bmc.1339","article-title":"Supported liquid extraction in combination with LC-MS\/MS for high-throughput quantitative analysis of hydrocortisone in mouse serum","volume":"24","author":"Wu","year":"2010","journal-title":"Biomedical Chromatography"},{"key":"2019071815300507500_bmy063C35","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/rcm.669","article-title":"A rapid and sensitive liquid chromatography\/negative ion tandem mass spectrometry method for the determination of an indolocarbazole in human plasma using 96-well diatomaceous earth plates for solid-liquid extraction [correction of using internal standard (IS) 96-well diatomaceous earth plates for solid-liquid extraction","volume":"16","author":"Wang","year":"2002","journal-title":"Rapid Communications In Mass Spectrometry"},{"key":"2019071815300507500_bmy063C36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jchromb.2008.12.006","article-title":"Using supported liquid extraction together with cellobiohydrolase chiral stationary phases-based liquid chromatography with tandem mass spectrometry for enantioselective determination of acebutolol and its active metabolite diacetolol in spiked human plasma","volume":"877","author":"Jiang","year":"2009","journal-title":"Journal of Chromatography B"},{"key":"2019071815300507500_bmy063C37","first-page":"430","article-title":"Supported liquid extraction: the best-kept secret in sample preparation","volume":"25","author":"Majors","year":"2012","journal-title":"LC-GC Europe"},{"key":"2019071815300507500_bmy063C38","author":"Cleeve","year":"2007"},{"key":"2019071815300507500_bmy063C39","author":"ICH","year":"2005"}],"container-title":["Journal of Chromatographic Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/chromsci\/article-pdf\/56\/10\/879\/26545268\/bmy063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T14:37:43Z","timestamp":1720363063000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/chromsci\/article\/56\/10\/879\/5049847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,6]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,7,6]]},"published-print":{"date-parts":[[2018,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/chromsci\/bmy063","relation":{},"ISSN":["0021-9665","1945-239X"],"issn-type":[{"value":"0021-9665","type":"print"},{"value":"1945-239X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,11]]},"published":{"date-parts":[[2018,7,6]]}}}